Evidence map›Paper›PMID 40000250›Full record

ArticleTherapeutic delivery2025

Gastroretentive microballoons of olmesartan medoxomil: formulation and

Archana S Patil, Shweta Aloshi, Yadishma Gaude, Rajashree S Masareddy

Abstract read
In one paragraph

Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Archana S PatilDepartment of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, India.ORCID 0000-0002-7458-8842
Shweta AloshiDepartment of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, India.
Yadishma GaudeDepartment of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, India.
Rajashree S MasareddyDepartment of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlmesartan medoxomil, classified as BCS class II due to its poor water solubility, exhibits a low oral bioavailability of 28.6%. MATERIALS AND

methodsMicroballoons of Olmesartan medoxomil were formulated using the ionotropic gelation technique and subjected to various evaluation parameters.

resultsThe particles were found to be in the range of 85.11 to 312.6 µm. The prepared microballoons remained buSSoyant for more than 12 hours and showed percentage of cumulative drug release between 56.32-83.62%.

conclusionThe formulated microballoons (hollow microspheres) emerged as a promising option for an oral gastro retentive controlled drug delivery system for Olmesartan medoxomil.

Indexed as

Drug CompoundingHypertensionMicrospheresOlmesartan MedoxomilAdministration, OralAnimalsAntihypertensive AgentsDelayed-Action PreparationsDisease Models, AnimalDrug LiberationMaleParticle SizeRatsRats, WistarSolubilityAntihypertensive AgentsDelayed-Action PreparationsOlmesartan Medoxomilfloating microballoonsHPMC K15MOlmesartan medoxomilsodium alginatesystolic blood pressure

Identifiers

PMID40000250
PMCPMC11875495

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.